Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) price-to-sales (or "P/S") ratio of 11.3x may look like a poor investment opportunity when you consider close to half the companies in the Pharmaceuticals industry in China have P/S ratios below 3.3x. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Shenzhen Chipscreen Biosciences

What Does Shenzhen Chipscreen Biosciences' P/S Mean For Shareholders?

Shenzhen Chipscreen Biosciences could be doing better as it's been growing revenue less than most other companies lately. One possibility is that the P/S ratio is high because investors think this lacklustre revenue performance will improve markedly. If not, then existing shareholders may be very nervous about the viability of the share price.

Want the full picture on analyst estimates for the company? Then our free report on Shenzhen Chipscreen Biosciences will help you uncover what's on the horizon.

How Is Shenzhen Chipscreen Biosciences' Revenue Growth Trending?

The only time you'd be truly comfortable seeing a P/S as steep as Shenzhen Chipscreen Biosciences' is when the company's growth is on track to outshine the industry decidedly.

Taking a look back first, we see that the company grew revenue by an impressive 21% last year. The strong recent performance means it was also able to grow revenue by 82% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenue over that time.

Looking ahead now, revenue is anticipated to climb by 40% during the coming year according to the one analyst following the company. That's shaping up to be materially lower than the 186% growth forecast for the broader industry.

With this in consideration, we believe it doesn't make sense that Shenzhen Chipscreen Biosciences' P/S is outpacing its industry peers. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. Only the boldest would assume these prices are sustainable as this level of revenue growth is likely to weigh heavily on the share price eventually.

The Bottom Line On Shenzhen Chipscreen Biosciences' P/S

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've concluded that Shenzhen Chipscreen Biosciences currently trades on a much higher than expected P/S since its forecast growth is lower than the wider industry. The weakness in the company's revenue estimate doesn't bode well for the elevated P/S, which could take a fall if the revenue sentiment doesn't improve. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Shenzhen Chipscreen Biosciences, and understanding should be part of your investment process.

If these risks are making you reconsider your opinion on Shenzhen Chipscreen Biosciences, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.